- Home
- SOL vs ZNTL Comparison
SOL vs ZNTL Comparison
Compare SOL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- ZNTL
- Stock Information
- Founded
- SOL 2005
- ZNTL 2014
- Country
- SOL United States
- ZNTL United States
- Employees
- SOL N/A
- ZNTL N/A
- Industry
- SOL Semiconductors
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- ZNTL Health Care
- Exchange
- SOL Nasdaq
- ZNTL Nasdaq
- Market Cap
- SOL 98.5M
- ZNTL 105.8M
- IPO Year
- SOL 2008
- ZNTL 2020
- Fundamental
- Price
- SOL $1.88
- ZNTL $1.49
- Analyst Decision
- SOL Strong Buy
- ZNTL Buy
- Analyst Count
- SOL 2
- ZNTL 7
- Target Price
- SOL $4.50
- ZNTL $8.46
- AVG Volume (30 Days)
- SOL 118.1K
- ZNTL 830.4K
- Earning Date
- SOL 11-13-2025
- ZNTL 11-11-2025
- Dividend Yield
- SOL N/A
- ZNTL N/A
- EPS Growth
- SOL N/A
- ZNTL N/A
- EPS
- SOL N/A
- ZNTL N/A
- Revenue
- SOL $68,445,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- SOL N/A
- ZNTL N/A
- Revenue Next Year
- SOL $45.37
- ZNTL N/A
- P/E Ratio
- SOL N/A
- ZNTL N/A
- Revenue Growth
- SOL N/A
- ZNTL N/A
- 52 Week Low
- SOL $1.04
- ZNTL $1.01
- 52 Week High
- SOL $3.00
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- SOL 53.12
- ZNTL 43.18
- Support Level
- SOL $1.81
- ZNTL $1.60
- Resistance Level
- SOL $1.88
- ZNTL $2.02
- Average True Range (ATR)
- SOL 0.03
- ZNTL 0.13
- MACD
- SOL 0.00
- ZNTL -0.04
- Stochastic Oscillator
- SOL 81.33
- ZNTL 5.36
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.